Perioperative management of antiplatelet therapy in patients with coronary stents undergoing cardiac and non-cardiac surgery

A consensus document from italian cardiological, surgical and anaesthesiological societies

Roberta Rossini, Giuseppe Musumeci, Luigi Oltrona Visconti, Ezio Bramucci, Battistina Castiglioni, Stefano De Servi, Corrado Lettieri, Maddalena Lettino, Emanuela Piccaluga, Stefano Savonitto, Daniela Trabattoni, Davide Capodanno, Francesca Buffoli, Alessandro Parolari, Gianlorenzo Dionigi, Luigi Boni, Federico Biglioli, Luigi Valdatta, Andrea Droghetti, Antonio Bozzani & 16 others Carlo Setacci, Paolo Ravelli, Claudio Crescini, Giovanni Staurenghi, Pietro Scarone, Luca Francetti, Fabio D'Angelo, Franco Gadda, Andrea Comel, Luca Salvi, Luca Lorini, Massimo Antonelli, Francesco Bovenzi, Alberto Cremonesi, Dominick J. Angiolillo, Giulio Guagliumi

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Optimal perioperative antiplatelet therapy in patients with coronary stents undergoing surgery still remains poorly defined and a matter of debate among cardiologists, surgeons and anaesthesiologists. Surgery represents one of the most common reasons for premature antiplatelet therapy discontinuation, which is associated with a significant increase in mortality and major adverse cardiac events, in particular stent thrombosis. Clinical practice guidelines provide little support with regard to managing antiplatelet therapy in the perioperative phase in the case of patients with non-deferrable surgical interventions and/or high haemorrhagic risk. Moreover, a standard definition of ischaemic and haemorrhagic risk has never been determined. Finally, recommendations shared by cardiologists, surgeons and anaesthesiologists are lacking. The present consensus document provides practical recommendations on the perioperative management of antiplatelet therapy in patients with coronary stents undergoing surgery. Cardiologists, surgeons and anaesthesiologists have contributed equally to its creation. On the basis of clinical and angiographic data, the individual thrombotic risk has been defined. All surgical interventions have been classified according to their inherent haemorrhagic risk. A consensus on the optimal antiplatelet regimen in the perioperative phase has been reached on the basis of the ischaemic and haemorrhagic risk. Aspirin should be continued perioperatively in the majority of surgical operations, whereas dual antiplatelet therapy should not be withdrawn for surgery in the case of low bleeding risk. In selected patients at high risk for both bleeding and ischaemic events, when oral antiplatelet therapy withdrawal is required, perioperative treatment with short-acting intravenous glycoprotein IIb/IIIa inhibitors (tirofiban or eptifibatide) should be taken into consideration.

Original languageEnglish
Pages (from-to)38-46
Number of pages9
JournalEuroIntervention
Volume10
Issue number1
DOIs
Publication statusPublished - 2014

Fingerprint

Stents
tirofiban
Therapeutics
Hemorrhage
Platelet Glycoprotein GPIIb-IIIa Complex
Practice Guidelines
Aspirin
Thrombosis
Mortality
Cardiologists
Surgeons

Keywords

  • Antiplatelet therapy
  • Aspirin
  • Coronary artery disease
  • PCI
  • Stent
  • Surgery

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Perioperative management of antiplatelet therapy in patients with coronary stents undergoing cardiac and non-cardiac surgery : A consensus document from italian cardiological, surgical and anaesthesiological societies. / Rossini, Roberta; Musumeci, Giuseppe; Visconti, Luigi Oltrona; Bramucci, Ezio; Castiglioni, Battistina; De Servi, Stefano; Lettieri, Corrado; Lettino, Maddalena; Piccaluga, Emanuela; Savonitto, Stefano; Trabattoni, Daniela; Capodanno, Davide; Buffoli, Francesca; Parolari, Alessandro; Dionigi, Gianlorenzo; Boni, Luigi; Biglioli, Federico; Valdatta, Luigi; Droghetti, Andrea; Bozzani, Antonio; Setacci, Carlo; Ravelli, Paolo; Crescini, Claudio; Staurenghi, Giovanni; Scarone, Pietro; Francetti, Luca; D'Angelo, Fabio; Gadda, Franco; Comel, Andrea; Salvi, Luca; Lorini, Luca; Antonelli, Massimo; Bovenzi, Francesco; Cremonesi, Alberto; Angiolillo, Dominick J.; Guagliumi, Giulio.

In: EuroIntervention, Vol. 10, No. 1, 2014, p. 38-46.

Research output: Contribution to journalArticle

Rossini, R, Musumeci, G, Visconti, LO, Bramucci, E, Castiglioni, B, De Servi, S, Lettieri, C, Lettino, M, Piccaluga, E, Savonitto, S, Trabattoni, D, Capodanno, D, Buffoli, F, Parolari, A, Dionigi, G, Boni, L, Biglioli, F, Valdatta, L, Droghetti, A, Bozzani, A, Setacci, C, Ravelli, P, Crescini, C, Staurenghi, G, Scarone, P, Francetti, L, D'Angelo, F, Gadda, F, Comel, A, Salvi, L, Lorini, L, Antonelli, M, Bovenzi, F, Cremonesi, A, Angiolillo, DJ & Guagliumi, G 2014, 'Perioperative management of antiplatelet therapy in patients with coronary stents undergoing cardiac and non-cardiac surgery: A consensus document from italian cardiological, surgical and anaesthesiological societies', EuroIntervention, vol. 10, no. 1, pp. 38-46. https://doi.org/10.4244/EIJV10I1A8
Rossini, Roberta ; Musumeci, Giuseppe ; Visconti, Luigi Oltrona ; Bramucci, Ezio ; Castiglioni, Battistina ; De Servi, Stefano ; Lettieri, Corrado ; Lettino, Maddalena ; Piccaluga, Emanuela ; Savonitto, Stefano ; Trabattoni, Daniela ; Capodanno, Davide ; Buffoli, Francesca ; Parolari, Alessandro ; Dionigi, Gianlorenzo ; Boni, Luigi ; Biglioli, Federico ; Valdatta, Luigi ; Droghetti, Andrea ; Bozzani, Antonio ; Setacci, Carlo ; Ravelli, Paolo ; Crescini, Claudio ; Staurenghi, Giovanni ; Scarone, Pietro ; Francetti, Luca ; D'Angelo, Fabio ; Gadda, Franco ; Comel, Andrea ; Salvi, Luca ; Lorini, Luca ; Antonelli, Massimo ; Bovenzi, Francesco ; Cremonesi, Alberto ; Angiolillo, Dominick J. ; Guagliumi, Giulio. / Perioperative management of antiplatelet therapy in patients with coronary stents undergoing cardiac and non-cardiac surgery : A consensus document from italian cardiological, surgical and anaesthesiological societies. In: EuroIntervention. 2014 ; Vol. 10, No. 1. pp. 38-46.
@article{b850ab967d064af084f642a6deef53dc,
title = "Perioperative management of antiplatelet therapy in patients with coronary stents undergoing cardiac and non-cardiac surgery: A consensus document from italian cardiological, surgical and anaesthesiological societies",
abstract = "Optimal perioperative antiplatelet therapy in patients with coronary stents undergoing surgery still remains poorly defined and a matter of debate among cardiologists, surgeons and anaesthesiologists. Surgery represents one of the most common reasons for premature antiplatelet therapy discontinuation, which is associated with a significant increase in mortality and major adverse cardiac events, in particular stent thrombosis. Clinical practice guidelines provide little support with regard to managing antiplatelet therapy in the perioperative phase in the case of patients with non-deferrable surgical interventions and/or high haemorrhagic risk. Moreover, a standard definition of ischaemic and haemorrhagic risk has never been determined. Finally, recommendations shared by cardiologists, surgeons and anaesthesiologists are lacking. The present consensus document provides practical recommendations on the perioperative management of antiplatelet therapy in patients with coronary stents undergoing surgery. Cardiologists, surgeons and anaesthesiologists have contributed equally to its creation. On the basis of clinical and angiographic data, the individual thrombotic risk has been defined. All surgical interventions have been classified according to their inherent haemorrhagic risk. A consensus on the optimal antiplatelet regimen in the perioperative phase has been reached on the basis of the ischaemic and haemorrhagic risk. Aspirin should be continued perioperatively in the majority of surgical operations, whereas dual antiplatelet therapy should not be withdrawn for surgery in the case of low bleeding risk. In selected patients at high risk for both bleeding and ischaemic events, when oral antiplatelet therapy withdrawal is required, perioperative treatment with short-acting intravenous glycoprotein IIb/IIIa inhibitors (tirofiban or eptifibatide) should be taken into consideration.",
keywords = "Antiplatelet therapy, Aspirin, Coronary artery disease, PCI, Stent, Surgery",
author = "Roberta Rossini and Giuseppe Musumeci and Visconti, {Luigi Oltrona} and Ezio Bramucci and Battistina Castiglioni and {De Servi}, Stefano and Corrado Lettieri and Maddalena Lettino and Emanuela Piccaluga and Stefano Savonitto and Daniela Trabattoni and Davide Capodanno and Francesca Buffoli and Alessandro Parolari and Gianlorenzo Dionigi and Luigi Boni and Federico Biglioli and Luigi Valdatta and Andrea Droghetti and Antonio Bozzani and Carlo Setacci and Paolo Ravelli and Claudio Crescini and Giovanni Staurenghi and Pietro Scarone and Luca Francetti and Fabio D'Angelo and Franco Gadda and Andrea Comel and Luca Salvi and Luca Lorini and Massimo Antonelli and Francesco Bovenzi and Alberto Cremonesi and Angiolillo, {Dominick J.} and Giulio Guagliumi",
year = "2014",
doi = "10.4244/EIJV10I1A8",
language = "English",
volume = "10",
pages = "38--46",
journal = "EuroIntervention",
issn = "1774-024X",
publisher = "EuroPCR",
number = "1",

}

TY - JOUR

T1 - Perioperative management of antiplatelet therapy in patients with coronary stents undergoing cardiac and non-cardiac surgery

T2 - A consensus document from italian cardiological, surgical and anaesthesiological societies

AU - Rossini, Roberta

AU - Musumeci, Giuseppe

AU - Visconti, Luigi Oltrona

AU - Bramucci, Ezio

AU - Castiglioni, Battistina

AU - De Servi, Stefano

AU - Lettieri, Corrado

AU - Lettino, Maddalena

AU - Piccaluga, Emanuela

AU - Savonitto, Stefano

AU - Trabattoni, Daniela

AU - Capodanno, Davide

AU - Buffoli, Francesca

AU - Parolari, Alessandro

AU - Dionigi, Gianlorenzo

AU - Boni, Luigi

AU - Biglioli, Federico

AU - Valdatta, Luigi

AU - Droghetti, Andrea

AU - Bozzani, Antonio

AU - Setacci, Carlo

AU - Ravelli, Paolo

AU - Crescini, Claudio

AU - Staurenghi, Giovanni

AU - Scarone, Pietro

AU - Francetti, Luca

AU - D'Angelo, Fabio

AU - Gadda, Franco

AU - Comel, Andrea

AU - Salvi, Luca

AU - Lorini, Luca

AU - Antonelli, Massimo

AU - Bovenzi, Francesco

AU - Cremonesi, Alberto

AU - Angiolillo, Dominick J.

AU - Guagliumi, Giulio

PY - 2014

Y1 - 2014

N2 - Optimal perioperative antiplatelet therapy in patients with coronary stents undergoing surgery still remains poorly defined and a matter of debate among cardiologists, surgeons and anaesthesiologists. Surgery represents one of the most common reasons for premature antiplatelet therapy discontinuation, which is associated with a significant increase in mortality and major adverse cardiac events, in particular stent thrombosis. Clinical practice guidelines provide little support with regard to managing antiplatelet therapy in the perioperative phase in the case of patients with non-deferrable surgical interventions and/or high haemorrhagic risk. Moreover, a standard definition of ischaemic and haemorrhagic risk has never been determined. Finally, recommendations shared by cardiologists, surgeons and anaesthesiologists are lacking. The present consensus document provides practical recommendations on the perioperative management of antiplatelet therapy in patients with coronary stents undergoing surgery. Cardiologists, surgeons and anaesthesiologists have contributed equally to its creation. On the basis of clinical and angiographic data, the individual thrombotic risk has been defined. All surgical interventions have been classified according to their inherent haemorrhagic risk. A consensus on the optimal antiplatelet regimen in the perioperative phase has been reached on the basis of the ischaemic and haemorrhagic risk. Aspirin should be continued perioperatively in the majority of surgical operations, whereas dual antiplatelet therapy should not be withdrawn for surgery in the case of low bleeding risk. In selected patients at high risk for both bleeding and ischaemic events, when oral antiplatelet therapy withdrawal is required, perioperative treatment with short-acting intravenous glycoprotein IIb/IIIa inhibitors (tirofiban or eptifibatide) should be taken into consideration.

AB - Optimal perioperative antiplatelet therapy in patients with coronary stents undergoing surgery still remains poorly defined and a matter of debate among cardiologists, surgeons and anaesthesiologists. Surgery represents one of the most common reasons for premature antiplatelet therapy discontinuation, which is associated with a significant increase in mortality and major adverse cardiac events, in particular stent thrombosis. Clinical practice guidelines provide little support with regard to managing antiplatelet therapy in the perioperative phase in the case of patients with non-deferrable surgical interventions and/or high haemorrhagic risk. Moreover, a standard definition of ischaemic and haemorrhagic risk has never been determined. Finally, recommendations shared by cardiologists, surgeons and anaesthesiologists are lacking. The present consensus document provides practical recommendations on the perioperative management of antiplatelet therapy in patients with coronary stents undergoing surgery. Cardiologists, surgeons and anaesthesiologists have contributed equally to its creation. On the basis of clinical and angiographic data, the individual thrombotic risk has been defined. All surgical interventions have been classified according to their inherent haemorrhagic risk. A consensus on the optimal antiplatelet regimen in the perioperative phase has been reached on the basis of the ischaemic and haemorrhagic risk. Aspirin should be continued perioperatively in the majority of surgical operations, whereas dual antiplatelet therapy should not be withdrawn for surgery in the case of low bleeding risk. In selected patients at high risk for both bleeding and ischaemic events, when oral antiplatelet therapy withdrawal is required, perioperative treatment with short-acting intravenous glycoprotein IIb/IIIa inhibitors (tirofiban or eptifibatide) should be taken into consideration.

KW - Antiplatelet therapy

KW - Aspirin

KW - Coronary artery disease

KW - PCI

KW - Stent

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=84902333427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902333427&partnerID=8YFLogxK

U2 - 10.4244/EIJV10I1A8

DO - 10.4244/EIJV10I1A8

M3 - Article

VL - 10

SP - 38

EP - 46

JO - EuroIntervention

JF - EuroIntervention

SN - 1774-024X

IS - 1

ER -